An observational study in Ventilated Patient in Intensive Care, sponsored by Centre Hospitalier Intercommunal Aix-Pertuis. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Centre Hospitalier Intercommunal Aix-Pertuis · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Pneumonia, Ventilator-Associated with a site in France — 20 open to participants now, 22 under way, 3 of them phase 3. Pneumonia, Ventilator-Associated · France.
Among the 80 studies in Pneumonia, Ventilator-Associated with a site in France, this one is the 31st largest by enrollment of the 33 observational ones that give a count, is one of 5 that started in 2025, is one of 33 observational ones, and was the 79th registered.
420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.
Browse Pneumonia, Ventilator-Associated studies →20 of the 80 studies in Pneumonia, Ventilator-Associated with a site in France are open now. Recruiting first, the newest first:
Region Skane · Sites in France, Portugal, Sweden
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
University Hospital, Limoges · Sites in France
Ages 18+
Nantes University Hospital · Sites in France, Guadeloupe
Ages 18+
Centre Hospitalier Sud Francilien · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 17 · Phase 4 2
First in 2003; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 170 across 132 observational studies indexed under Pneumonia, Ventilator-Associated.
Median enrollment 161 across the 47 interventional studies, 268 across the 33 observational. Of the 49 that completed or were terminated, 7 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 80 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Intercommunal Aix-Pertuis is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Centre Hospitalier Intercommunal Aix-Pertuis has 2 studies filed under Pneumonia, Ventilator-Associated — fewer than ten, so there is no comparison to draw.
7 of the studies in Pneumonia, Ventilator-Associated with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05843786Phase 3Hospices Civils de LyonHuman Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients | 2027-07-30 |
| NCT06607055Centre Hospitalier Intercommunal Aix-PertuisImmunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia | 2026-12 |
| NCT05719259European Clinical Research Alliance for Infectious Diseases (ECRAID)Perpetual Observational Study - Ventilator Associated Pneumonia | 2026-12-01 |
| NCT06653933University Hospital, GrenobleStudy of Sleep Quality in the Intensive Care Unit and Association with Weaning from Invasive Ventilation in Patients with Chronic Obstructive Bronchopneumopathy. | 2027-02-01 |
| NCT05915663Centre Hospitalier le MansImpact of the Choice of Gastric Tube Placement Sites on the Incidence of Ventilator Associated Pneumonia | 2027-04-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies in Pneumonia, Ventilator-Associated with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Ventilator-associated pneumonia (VAP) is defined as an infection of the lung parenchyma in patients undergoing invasive mechanical ventilation for at least 48 hours. It is one of the types of pneumonia acquired in intensive care units (ICUs) and is one of the most common infections in this population, representing a major complication.
The diagnosis of VAP is based on three main criteria: clinical suspicion, adiological imaging, and microbiological cultures of the lower respiratory tract. However, these elements have significant limitations.
New rapid diagnostic techniques, such as multiplex polymerase chain reaction (PCR), can quickly identify pathogens and resistance mechanisms in just a few hours. These promising tools could reduce the time to initiate targeted treatment while limiting the excessive use of antibiotics. However, no single tool is currently accurate enough to diagnose VAP, and diagnosis is based on a combination of factors.
Today, scores exist that can be used to assess the probability of PAVM, such as the CIPS. These are useful tools but lack specificity. The clinical, biological and radiological criteria used to calculate the score can also be observed in other pathologies. Thus, although they are sensitive to the detection of PAVM, they are often insufficient to establish a definitive diagnosis. They must be supplemented by other diagnostic approaches, such as microbiological cultures and more detailed imaging examinations, to obtain a more accurate assessment.
It is also essential to mention the importance of gaining a better understanding of the lung microbiome. Indeed, it appears to play a central role not only in the pathophysiology of MVAP, but also in its diagnosis and management.
The work of Fromentin et al. shows that it is possible to observe dysbiosis associated with a loss of microbial diversity and the onset of certain pulmonary infections. Thus, structural variations in mucus could reflect changes in the pulmonary microbiome.
It is therefore essential to remember that mucus plays an essential protective role in the respiratory tract by trapping particles, bacteria and pathogens, while facilitating their transport thanks to its viscoelastic properties. However, in mechanically ventilated patients, these mucociliary clearance mechanisms are often impaired, promoting the accumulation of secretions, bacterial proliferation and, ultimately, the onset of MVAP.
The work of Patarin and Giovanna and al. suggests that biochemical and microbiological changes in mucus could be a criterion for initiating treatment in recurrent pulmonary infections in patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis. These observations suggest the potential value of early characterisation of mucus in ventilated patients in order to detect additional diagnostic clues that would enable rapid and appropriate treatment.
Nowadays, micro-rheological analyses make it possible to accurately measure the viscoelastic properties of mucus directly at the patient's bedside. These tools offer a unique opportunity to explore bronchial secretions as an element for early diagnosis, monitoring and personalisation of FMAP treatments.
These analyses are based on mucus sampling, which is performed by bronchial aspiration. This is a simple, quick procedure that is commonly performed on demand in intensive care units to prevent complications, particularly airway obstruction.
There are no prospective studies on specific rheological markers in the prediction of FMAP, making it necessary to explore their role in the pathophysiology, diagnosis and management of this condition in greater depth.
Ventilated patient in intensive care in the hospital of Aix-en-Provence
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Tracheobronchial suction is performed on request through the intubation tube or tracheotomy cannula to collect this mucus. Instead of being discarded, this sample will be stored. Within one hour of collection, the viscoelastic characteristics of this mucus will be studied. This analysis can only be performed once per day per patient. Samples will be collected daily until mechanical ventilation is discontinued.
Describe changes in the viscoelastic properties of mucus over time in patients on mechanical ventilation
Time frame: From date of initiation of mechanical ventilation up to the date of extubation or tracheostomy decannulation, assessed up to 30 days
Highlight a correlation between changes in viscoelastic characteristics and the secondary onset of PAVM
Time frame: From date of initiation of mechanical ventilation up to the date of extubation or tracheostomy decannulationn assessed up to 30 days
Highlight that changes in the viscoelastic properties of mucus precede the onset and therefore the diagnosis of PAVM
Time frame: From date of initiation of mechanical ventilation up to the date of extubation or tracheostomy decannulationn assessed up to 30 days
Propose a threshold for variation in viscoelastic parameters that allows patients with PAVM to be distinguished from those who do not develop it
Time frame: one year
Enable early bacterial identification by rheological signature
Time frame: one year
Plan to share: No
Ran from Mar 2025 to primary completion in Mar 2026, 12 months.
Of 63 non-industry observational studies under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 12 months is below that.
Counting every sponsor, half of 63 studies reached it within 20 months; a quarter within 12 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pneumonia, Ventilator-Associated →
Centre Hospitalier Intercommunal Aix-Pertuis